Compare CATY & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | IDYA |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 1996 | 2019 |
| Metric | CATY | IDYA |
|---|---|---|
| Price | $48.95 | $34.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $52.75 | $51.21 |
| AVG Volume (30 Days) | 338.4K | ★ 741.6K |
| Earning Date | 04-23-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | 14.94 | ★ 61.90 |
| EPS | ★ 4.54 | N/A |
| Revenue | $53,793,000.00 | ★ $218,710,000.00 |
| Revenue This Year | $20.37 | N/A |
| Revenue Next Year | $5.41 | $97.58 |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | 2.93 | ★ 3024.43 |
| 52 Week Low | $36.06 | $13.45 |
| 52 Week High | $54.99 | $39.28 |
| Indicator | CATY | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 37.53 | 58.75 |
| Support Level | $48.02 | $32.85 |
| Resistance Level | $49.21 | $37.08 |
| Average True Range (ATR) | 1.46 | 1.59 |
| MACD | -0.54 | 0.32 |
| Stochastic Oscillator | 9.58 | 80.84 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.